{"id":745391,"date":"2016-04-19T13:05:00","date_gmt":"2016-04-19T13:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/"},"modified":"2025-11-07T01:25:54","modified_gmt":"2025-11-07T06:25:54","slug":"merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/","title":{"rendered":"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada, is<br \/>\n      proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an<br \/>\n      important initiative to compare several new diagnostic tests for the<br \/>\n      immune biomarker PD-L1 in non-small cell lung cancer (NSCLC). Merck<br \/>\n      believes strongly in the importance of PD-L1 testing in NSCLC, and is<br \/>\n      committed to supporting the Blueprint Project and overall efforts to use<br \/>\n      diagnostics to help physicians identify the best treatment approach for<br \/>\n      their patients with some cancers.\n    <\/p>\n<p>\n      In oncology, testing is now common for numerous cancer biomarkers to<br \/>\n      enable physicians to better tailor treatment decisions for each patient.<br \/>\n      The data from a range of studies, including Merck\u2019s studies of KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), demonstrate that PD-L1 testing can be a useful tool to<br \/>\n      help identify patients more likely to respond to treatment with an<br \/>\n      anti-PD-1\/PD-L1 therapy in certain cancers, including NSCLC.\n    <\/p>\n<p>\n      Phase 1 of the Blueprint Project is an important step toward<br \/>\n      understanding the usefulness of the different PD-L1 testing approaches.<br \/>\n      Analyses from the Blueprint Project confirm that there is high<br \/>\n      concordance for the two approved PD-L1 diagnostics in NSCLC, including<br \/>\n      the one used in conjunction with KEYTRUDA, the PD-L1 IHC 22C3 pharmDx<br \/>\n      assay developed in partnership with Dako North America, Inc., an Agilent<br \/>\n      Technologies Company.\n    <\/p>\n<p>\n      \u201cWe are very encouraged by the findings from the Blueprint Project, and<br \/>\n      are eager to support the greater use of biomarker testing to advance the<br \/>\n      care of patients with cancer,\u201d said Dr. Roy Baynes, senior vice<br \/>\n      president and head of global clinical development, Merck Research<br \/>\n      Laboratories. \u201cThis analysis reinforces our precision medicine approach<br \/>\n      in NSCLC to help provide physicians and patients with greater insight<br \/>\n      into each patient&#8217;s disease and therefore greater confidence in their<br \/>\n      treatment decisions.&#8221;\n    <\/p>\n<p>\n      Merck is a leader in advancing immuno-oncology through the development<br \/>\n      of KEYTRUDA (pembrolizumab) alongside its Dako companion diagnostic. We<br \/>\n      are continuing to build our knowledge of genetics and biomarkers in<br \/>\n      order to ensure we can match KEYTRUDA with patients who are more likely<br \/>\n      to experience benefit.\n    <\/p>\n<p>\n      <b>About the Blueprint Project<\/b>\n    <\/p>\n<p>\n      Results from the Blueprint Project, a first-of-its kind collaboration,<br \/>\n      were presented at the American Association for Cancer Research 2016<br \/>\n      Annual Meeting.\n    <\/p>\n<p>\n      In March 2015, the AACR in partnership with the U.S. Food and Drug<br \/>\n      Administration and the American Society of Clinical Oncology held a<br \/>\n      one-day workshop to examine whether multiple companion diagnostics<br \/>\n      intended for the same class of therapeutics could be harmonized. During<br \/>\n      the workshop, a group of four pharmaceutical companies and two<br \/>\n      diagnostic companies released a blueprint proposal to analytically<br \/>\n      compare and characterize each of their IHC-based PD-1\/PD-L1 companion<br \/>\n      diagnostics for non-small cell lung cancer in the pre-approval stage.<br \/>\n      The thought was that, upon approval of these tests, the information<br \/>\n      generated by this project could lay the groundwork for additional<br \/>\n      studies that will help inform patients, physicians, pathologists, and<br \/>\n      others on how best to use the test results to determine treatment<br \/>\n      decisions.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States for the treatment of patients<br \/>\n      with unresectable or metastatic melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. The NSCLC<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is administered at a dose of 2 mg\/kg as an<br \/>\n      intravenous infusion over 30 minutes every three weeks for the approved<br \/>\n      indications.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b>\u00a0(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis occurred in 19 (3.5%) of 550 patients,<br \/>\n      including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis<br \/>\n      and occurred more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients, including<br \/>\n      Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as clinically indicated.<br \/>\n      Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3 or 4<br \/>\n      hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%) hyperthyroidism. Hypothyroidism occurred in 38 (6.9%)<br \/>\n      of 550 patients, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA (pembrolizumab) and administer anti-hyperglycemics<br \/>\n      in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients. Serious adverse reactions occurred in 38% of patients. The<br \/>\n      most frequent serious adverse reactions reported in at least 2% of<br \/>\n      patients were pleural effusion, pneumonia, dyspnea, pulmonary embolism,<br \/>\n      and pneumonitis. The most common adverse reactions (reported in at least<br \/>\n      20% of patients) were fatigue (44%), cough (29%), decreased appetite<br \/>\n      (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=fe6b8df8085014ed9d0337efabd024e1\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=86432dc5829ffaaa6fafc589de9ef9d2\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=7111f6eab068518842c90b4d54fd2bf6\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=0d1c00b1457af299ceb71c90eafdadbb\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=307fa5a8b3329eb9d937d6360dcffe1a\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=fe2212b65535ae059d7711a112de1449\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=59a408e68aa3d64c75af8c721506468a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=4d2452d0740cea80e56c1e805f04ab3c\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51323588&amp;newsitemid=20160419006579&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=6dc77e7ead92cf7fc3bf6799ecbe8762\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160419006579r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>An Phan,        908-255-6325<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC). Merck believes strongly in the importance of PD-L1 testing in NSCLC, and is committed to supporting the Blueprint Project and overall efforts to use diagnostics to help physicians identify the best treatment approach for their patients with some cancers. In oncology, testing is now common for numerous cancer biomarkers to enable physicians to better tailor treatment decisions for each patient. The data from a range of studies, including Merck\u2019s studies of KEYTRUDA\u00ae (pembrolizumab), demonstrate that PD-L1 testing can be a useful tool to help identify patients more likely to respond to treatment with an anti-PD-1\/PD-L1 therapy in certain cancers, including NSCLC. Phase 1 of the Blueprint Project is an important step<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-745391","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC). Merck believes strongly in the importance of PD-L1 testing in NSCLC, and is committed to supporting the Blueprint Project and overall efforts to use diagnostics to help physicians identify the best treatment approach for their patients with some cancers. In oncology, testing is now common for numerous cancer biomarkers to enable physicians to better tailor treatment decisions for each patient. The data from a range of studies, including Merck\u2019s studies of KEYTRUDA\u00ae (pembrolizumab), demonstrate that PD-L1 testing can be a useful tool to help identify patients more likely to respond to treatment with an anti-PD-1\/PD-L1 therapy in certain cancers, including NSCLC. Phase 1 of the Blueprint Project is an important step\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\\\/\",\"name\":\"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-04-19T13:05:00+00:00\",\"dateModified\":\"2025-11-07T06:25:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC). Merck believes strongly in the importance of PD-L1 testing in NSCLC, and is committed to supporting the Blueprint Project and overall efforts to use diagnostics to help physicians identify the best treatment approach for their patients with some cancers. In oncology, testing is now common for numerous cancer biomarkers to enable physicians to better tailor treatment decisions for each patient. The data from a range of studies, including Merck\u2019s studies of KEYTRUDA\u00ae (pembrolizumab), demonstrate that PD-L1 testing can be a useful tool to help identify patients more likely to respond to treatment with an anti-PD-1\/PD-L1 therapy in certain cancers, including NSCLC. Phase 1 of the Blueprint Project is an important step","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:54+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/","name":"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-04-19T13:05:00+00:00","dateModified":"2025-11-07T06:25:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-blueprint-project-findings-presented-at-the-american-association-for-cancer-research-2016-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"552dc471-b364-4db8-a401-3ff97234e551","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745391\/revisions"}],"predecessor-version":[{"id":3674785,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745391\/revisions\/3674785"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745391"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}